ELV Stock Analysis: Elevance Health | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 96.568m USD | 12M Return: 29.6% | US0367521038 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 516M
EPS Trend: -84.7%
Qual. Beats: 3
Rev. Trend: 97.1%
Qual. Beats: 10
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Elevance Health, Inc. is a U.S.-based health benefits company headquartered in Indianapolis, Indiana, that operates through four reportable segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company provides health plans and related services to individual, employer group, BlueCard, Medicare, Medicaid, and Federal Employees Program (FEP) members, while also offering specialty and supplemental products such as dental, vision, and stop loss insurance. Its pharmacy services business, branded CarelonRx, includes home delivery, specialty pharmacies, claims adjudication, formulary management, rebate administration, and infusion services, and its Carelon Services segment delivers care management, behavioral health, palliative care, virtual care, payment integrity, clinical analytics, and post-acute and home-based care support. The company markets its offerings under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands, and was renamed from Anthem, Inc. to Elevance Health, Inc. in June 2022.
As one of the major publicly traded U.S. managed care organizations in the GICS Managed Health Care sub-industry, Elevance Health operates an integrated payer-and-services model in which the same company underwrites insurance risk (its Blue-licensed health plans), administers pharmacy benefits, and sells care-delivery-adjacent services to other insurers and providers. This vertical integration-combining a health insurer with a captive PBM and a portfolio of clinical and administrative services-has become a common structural approach among large U.S. health plans seeking to capture additional margin across the healthcare value chain.
- Medicare Advantage medical costs pressure benefit ratios
- CarelonRx pharmacy segment drives margin expansion
- Medicaid redeterminations pressure state contract margins
| Net Income: 5.14b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.03 > 1.0 |
| NWC/Revenue: 10.83% < 20% (prev 2.72%; Δ 8.11% < -1%) |
| CFO/TA 0.06 > 3% & CFO 7.60b > Net Income 5.14b |
| Net Debt (20.8b) to EBITDA (8.88b): 2.35 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (217.6m) vs 12m ago -3.63% < -2% |
| Gross Margin: 36.55% > 18% (prev 26.26%; Δ 10.29% > 0.5%) |
| Asset Turnover: 161.1% > 50% (prev 158.7%; Δ 2.40% > 0%) |
| Interest Coverage Ratio: 6.50 > 6 (EBIT TTM 7.39b / Interest Expense TTM 1.14b) |
| A: 0.17 (Total Current Assets 68.5b - Total Current Liabilities 46.7b) / Total Assets 128b |
| B: 0.29 (Retained Earnings 37.4b / Total Assets 128b) |
| C: 0.06 (EBIT TTM 7.39b / Avg Total Assets 125b) |
| D: 0.54 (Book Value of Equity 44.7b / Total Liabilities 83.0b) |
| Altman-Z'' = 3.04 = A |
As of October 25, 2026, the stock is trading at USD 439.95 with a total of 1,173,637 shares traded. Over the past week, the price has changed by +2.73%, over one month by +10.38%, over three months by +16.49% and over the past year by +29.58%.
Current recommended Stop Loss: 419.10 (which is 4.7% or 1.8 ATR below the current price).
Elevance Health has received a consensus analysts rating of 4.18. Therefore, it is recommended to buy ELV.
- StrongBuy: 12
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 479.6 | 9% |
P/E Trailing = 18.9079
P/E Forward = 13.6799
P/S = 0.4802
P/B = 1.9258
P/EG = 1.3035
Revenue TTM = 202b USD
EBIT TTM = 7.39b USD
EBITDA TTM = 8.88b USD
Long Term Debt = 30.8b USD (from longTermDebt, last fiscal year)
Short Term Debt = 375.0m USD (from shortTermDebt, last quarter)
Debt = 31.2b USD (corrected: LT Debt 30.8b + ST Debt 375.0m)
Net Debt = 20.8b USD (calculated: Debt 31.2b - CCE 10.3b)
Enterprise Value = 117b USD (96.6b + Debt 31.2b - CCE 10.3b)
Interest Coverage Ratio = 6.50 (Ebit TTM 7.39b / Interest Expense TTM 1.14b)
EV/FCF = 18.02x (Enterprise Value 117b / FCF TTM 6.51b)
FCF Yield = 5.55% (FCF TTM 6.51b / Enterprise Value 117b)
FCF Margin = 3.23% (FCF TTM 6.51b / Revenue TTM 202b)
Net Margin = 2.55% (Net Income TTM 5.14b / Revenue TTM 202b)
Gross Margin = 36.55% ((Revenue TTM 202b - Cost of Revenue TTM 128b) / Revenue TTM)
Gross Margin QoQ = 15.57% (prev 89.12%)
Tobins Q-Ratio = 0.92 (Enterprise Value 117b / Total Assets 128b)
Interest Expense / Debt = 3.65% (Interest Expense 1.14b / Debt 31.2b)
Taxrate = 18.35% (1.15b / 6.25b)
NOPAT = 6.03b (EBIT 7.39b * (1 - 18.35%))
Current Ratio = 1.47 (Total Current Assets 68.5b / Total Current Liabilities 46.7b)
Debt / Equity = 0.70 (Debt 31.2b / totalStockholderEquity, last quarter 44.7b)
Debt / EBITDA = 2.35 (Net Debt 20.8b / EBITDA 8.88b)
Debt / FCF = 3.20 (Net Debt 20.8b / FCF TTM 6.51b)
Total Stockholder Equity = 44.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.10% (Net Income 5.14b / Total Assets 128b)
RoE = 11.59% (Net Income TTM 5.14b / Total Stockholder Equity 44.3b)
RoCE = 9.83% (EBIT 7.39b / Capital Employed (Equity 44.3b + L.T.Debt 30.8b))
RoIC = 8.44% (NOPAT 6.03b / Invested Capital 71.4b)
WACC = 4.89% (E(96.6b)/V(128b) * Re(5.51%) + D(31.2b)/V(128b) * Rd(3.65%) * (1-Tc(0.18)))
Discount Rate = 5.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.82 | Cagr: -3.07%
[DCF] Terminal Value 77.97% ; FCFF base≈5.42b ; Y1≈6.21b ; Y5≈9.14b
[DCF] Fair Price = 537.9 (EV 137b - Net Debt 20.8b = Equity 117b / Shares 216.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -84.67 | EPS CAGR: -5.81% | SUE: 2.45 | # QB: 3
Revenue Correlation: 97.06 | Revenue CAGR: 7.70% | SUE: 4.0 | # QB: 10
EPS current Quarter (2027-03-31): EPS=12.26 | Chg30d=+1.15% | Revisions=+25% | Analysts=13
EPS current Year (2026-12-31): EPS=28.79 | Chg30d=+5.96% | Revisions=+50% | GrowthEPS=-5.0% | GrowthRev=+0.5%
EPS next Year (2027-12-31): EPS=30.15 | Chg30d=+2.06% | Revisions=+17% | GrowthEPS=+4.7% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: +50% (up=6, down=1)